Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34)
Description
Grant Amount: Unspecified.
This FOA is issued by the National institute on Drug Abuse (NIDA), National Institutes of Health for R34 applications, and provides resources to support (a) pilot or feasibility studies of new or adapted interventions to prevent HIV infection among populations where substance use may be a contributing factor; (b) pilot or feasibility studies of new or adapted interventions to improve the care of HIV infection among populations where substance use is prevalent, including interventions that integrate treatment for substance use disorders and HIV infection; or (c) pilot or feasibility studies to increase the scale, uptake, delivery, and/or quality of HIV prevention or care interventions with established evidence of efficacy. Both primary and secondary prevention will be supported. The full range of substance use will be considered including problematic episodic use and substance use disorders, as well as a full range of substances and modes of administration. The most important consideration is that substance use may affect transmission directly as in the case of injection drug use or may affect transmission risk behavior. Domestic and overseas populations will be considered, with particular attention to populations with disproportionate burden of HIV infection and those where HIV infection and/or drug use are emergent.
Funding Organization
National Institute on Drug Abuse
Fund Category
HIV/AIDS
Support Types
Research
Locations
International National
Eligible Organizations
City Agencies Colleges/Universities Commercial Organizations Community Based Organizations County Agencies Educational Organizations/Institutions Federal Government Agencies International Agencies IRS 501 (c)(3) Organizations Nonprofit Organizations Religious Organizations Schools State Agencies Tribal Organizations
Award Amount Notes
The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications.
Direct costs are limited to $450,000 over a three-year period, with no more than $225,000 direct costs allowed in any single year.
Application Due Date
5/7/2013
Project Start Date
9/1/2013
Application Contact
Grants.gov Customer Support , Phone: (800) 518-4726
Technical Contact
Richard A Jenkins Prevention Research BranchDiv of Epi, Svcs & Prev Rsch NIDA 6001 Executive Blvd. Rm. 5185 MSC 9589 Bethesda, MD 208929589 Phone: (301) 443-1923 Fax: (301) 480-2542
Fund Duration
Up to 3 years.
Subjects
Clinical Trials Drug Abuse Health Care Programs/Services HIV/AIDS Prevention Medical Treatments and Therapies Research Programs Substance Abuse Treatment and Counseling
Audiences
Researchers
Application Process
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.
